{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:25:50Z","timestamp":1793157950471,"version":"4.5.0"},"reference-count":18,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Agranulocytosis is a rare but serious complication of antithyroid drug (ATD) therapy. Characteristics of agranulocytosis have been reported in only a small number of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>We studied 754 cases of ATD-induced agranulocytosis reported over 30 years. The age distribution and sex ratio were compared with those in 12 503 untreated Graves' patients at Kuma Hospital. The annual number of new Graves' patients in Japan was estimated from the Japan Medical Data Center Data Mart-Pharmacovigilance health insurance receipt database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Agranulocytosis developed within 90 days after starting ATD therapy in most patients (84.5%). The methimazole dose given at onset was 25.2 \u00b1 12.8 mg\/d (mean \u00b1 SD). The mean age was 43.4 \u00b1 15.2 years, and the male to female ratio was 1:6.3. When compared with patients at Kuma Hospital, patients with agranulocytosis were older (P &amp;lt; .001) and more females (P &amp;lt; .0001). Of 211 patients with more than 1 granulocyte measurement before onset, 131 (62%) showed normal counts (&amp;gt;1000\/\u03bcL) within 2 weeks before onset, demonstrating real sudden onset of agranulocytosis. In contrast, some of the 20 patients with more than 4 measurements showed gradual decreases in granulocyte counts. Analysis of physician reports for 30 fatal cases revealed that some deaths might have been prevented. The number of new Graves' patients treated with ATD was estimated at about 35 000 per year, and the incidence rate of agranulocytosis was 0.1% to 0.15% in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This is the largest study of agranulocytosis. Agranulocytosis tends to occur abruptly within 3 months after initiation of ATD therapy, although it develops gradually in some patients. Providing every patient with sufficient information on agranulocytosis is critical.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2013-2569","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T21:58:06Z","timestamp":1379714286000},"page":"4776-4783","source":"Crossref","is-referenced-by-count":153,"title":["Analysis of 754 Cases of Antithyroid Drug-Induced Agranulocytosis Over 30 Years in Japan"],"prefix":"10.1210","volume":"98","author":[{"given":"Hirotoshi","family":"Nakamura","sequence":"first","affiliation":[{"name":"Kuma Hospital, Chugai Pharmaceutical Co, Ltd (H.N., A.M.), Shimoyamate-dori, Chuo-ku, Kobe 650\u20130011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Kuma Hospital, Chugai Pharmaceutical Co, Ltd (H.N., A.M.), Shimoyamate-dori, Chuo-ku, Kobe 650\u20130011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Miyawaki","sequence":"additional","affiliation":[{"name":"Nihonbashi-Muromachi 2-Chome (N.M., J.I.), Chuo-ku, Tokyo 103\u20138324, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Imagawa","sequence":"additional","affiliation":[{"name":"Nihonbashi-Muromachi 2-Chome (N.M., J.I.), Chuo-ku, Tokyo 103\u20138324, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616450835100_B1","first-page":"492","article-title":"2013 Treatment of thyrotoxicosis","volume-title":"Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text","author":"Cooper","year":"2013","edition":"10th ed"},{"key":"2020071616450835100_B2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","journal-title":"N Engl J Med"},{"key":"2020071616450835100_B3","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","article-title":"Clinical practice. Graves' disease","volume":"358","author":"Brent","year":"2008","journal-title":"N Engl J Med"},{"key":"2020071616450835100_B4","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(11)60782-4","article-title":"Thyrotoxicosis","volume":"379","author":"Franklyn","year":"2012","journal-title":"Lancet"},{"key":"2020071616450835100_B5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2010.0417","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"21","author":"Bahn Chair","year":"2011","journal-title":"Thyroid"},{"key":"2020071616450835100_B6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archinte.1990.00390150107020","article-title":"Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring","volume":"150","author":"Tajiri","year":"1990","journal-title":"Arch Intern Med"},{"key":"2020071616450835100_B7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-98-1-26","article-title":"Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose","volume":"98","author":"Cooper","year":"1983","journal-title":"Ann Intern Med"},{"key":"2020071616450835100_B8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1507\/endocrj.49.29","article-title":"Retrospective analysis of 18 cases of antithyroid drug (ATD)-induced agranulocytosis","volume":"49","author":"Dai","year":"2002","journal-title":"Endocr J"},{"key":"2020071616450835100_B9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2265.2004.02135.x","article-title":"Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK","volume":"61","author":"Pearce","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616450835100_B10","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/archinte.144.8.1687","article-title":"Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis","volume":"144","author":"Guffy","year":"1984","journal-title":"Arch Intern Med"},{"key":"2020071616450835100_B11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.1986.tb04130.x","article-title":"Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells","volume":"64","author":"Fibbe","year":"1986","journal-title":"Br J Haematol"},{"key":"2020071616450835100_B12","first-page":"124","article-title":"Immunological: reactions involving leukocytes. III. Agranulocytosis induced by antithyroid drugs","volume":"138","author":"Bilezikian","year":"1976","journal-title":"Johns Hopkins Med J"},{"key":"2020071616450835100_B13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1210\/jcem-58-5-868","article-title":"In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis","volume":"58","author":"Wall","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616450835100_B14","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1210\/jc.2006-2135","article-title":"Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease","volume":"92","author":"Nakamura","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616450835100_B15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/thy.2008.0364","article-title":"Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily","volume":"19","author":"Takata","year":"2009","journal-title":"Thyroid"},{"key":"2020071616450835100_B16","volume-title":"Guidelines for the Treatment of Graves' Disease in Japan","author":"Japan Thyroid Association","year":"2011"},{"key":"2020071616450835100_B17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions : a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"2020071616450835100_B18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/pds.3378","article-title":"Factors associated with spontaneous reporting of adverse drug reactions in Japan","volume":"22","author":"Yamada","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/12\/4776\/11128034\/jcem4776.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/12\/4776\/11128034\/jcem4776.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:25:33Z","timestamp":1594941933000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/12\/4776\/2834507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,1]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-2569","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,1]]}}}